CLINICAL TRIAL: PHASE 2: CCI-779 IN COMBINATION WITH BEVACIZUMAB IN STAGE III OR
CLINICAL TRIAL: PHASE 2: CCI-779 IN COMBINATION WITH BEVACIZUMAB IN STAGE III OR
批准号:
7951485
负责人:
Craig Lee Slingluff
金额:
$15.01万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-03-01 至 2010-02-28
关键词:
Biological MarkersCCI-779ClinicalClinical ResearchComputer Retrieval of Information on Scientific Projects DatabaseDoseEvaluationFundingGoalsGrantInstitutionInvestigationMolecular TargetMonitorNational Cancer InstituteOutcomeParticipantPatientsPhasePhase II Clinical TrialsResearchResearch PersonnelResourcesSafetyScheduleSeriesSiteSourceSpecific qualifier valueStagingUnited States National Institutes of Healthbevacizumabdesignmelanoma
中文摘要
这个子项目是许多研究子项目中利用
资源由NIH/NCRR资助的中心拨款提供。子项目和
调查员(PI)可能从NIH的另一个来源获得了主要资金,
并因此可以在其他清晰的条目中表示。列出的机构是
该中心不一定是调查人员的机构。
这是对患有III或IV期黑色素瘤的参与者进行的贝伐单抗加CCI-779的多部位II期评估。多达23名参与者将接受研究治疗。主要目标是确定贝伐单抗加CCI-779在指定剂量和时间表下的治疗是否可以产生足够的临床活性来对抗黑色素瘤,值得进一步研究。
治疗将包括26个周期。每个周期为14天。CCI-779将在第1-26周期的第1天和第8天给药。贝伐单抗将在第1-26周期的第8天给药。在整个研究过程中,将每月监测所有参与者的安全信息。将使用两阶段设计来确定是否应因抗肿瘤活性不足而停止应计。
这项研究是美国国家癌症研究所赞助的一系列研究之一,该研究参与了分子靶向联合相关(MTC2)研究计划,以评估与靶向药物治疗的患者结果相关的可能的生物标记物。
英文摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
This is a multi site phase II evaluation of bevacizumab plus CCI-779, in participants with stage III or IV melanoma. Up to 23 participants will receive study treatment. The primary goal is to ascertain whether treatment with bevacizumab plus CCI-779 at the specified doses and schedule can produce sufficient clinical activity against melanoma to warrant further investigation.
Treatment will consist of 26 cycles. Each cycle is 14 days. CCI-779 will be administered on days 1 and 8 of cycles 1-26. Bevacizumab will be administered on day 8 of cycles 1-26. Safety information will be monitored monthly on all participants throughout the study. A 2-staged design will be used to determine if accrual should be halted due to insufficient antitumor activity.
This study is one of a series of National Cancer Institute sponsored studies participating in the Molecular Targeted Combinations Correlative (MTC2) Study Initiative to evaluate possible biomarkers that correlate with patient outcomes to treatment with targeted agents.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Antibodies to melanoma vaccine peptides
-
批准号:9378813
-
项目类别:
-
资助金额:$8.05万
-
财政年份:2017
-
负责人:Craig Lee Slingluff
-
依托单位:
MELANOMA VACCINE FOR HELPER T CELLS COMBINED WITH TARGETED OR IMMUNE THERAPIES
-
批准号:9295843
-
项目类别:
-
资助金额:$39.48万
-
财政年份:2013
-
负责人:Craig Lee Slingluff
-
依托单位:
MELANOMA VACCINE FOR HELPER T CELLS COMBINED WITH TARGETED OR IMMUNE THERAPIES
-
批准号:8692713
-
项目类别:
-
资助金额:$38.94万
-
财政年份:2013
-
负责人:Craig Lee Slingluff
-
依托单位:
MELANOMA VACCINE FOR HELPER T CELLS COMBINED WITH TARGETED OR IMMUNE THERAPIES
-
批准号:8561255
-
项目类别:
-
资助金额:$40.14万
-
财政年份:2013
-
负责人:Craig Lee Slingluff
-
依托单位:
MELANOMA VACCINE FOR HELPER T CELLS COMBINED WITH TARGETED OR IMMUNE THERAPIES
-
批准号:8915646
-
项目类别:
-
资助金额:$39.48万
-
财政年份:2013
-
负责人:Craig Lee Slingluff
-
依托单位:
PHASE 2: CCI-779 IN COMBINATION WITH BEVACIZUMAB IN STAGE III OR IV MELANOMA
-
批准号:8167165
-
项目类别:
-
资助金额:$4.41万
-
财政年份:2010
-
负责人:Craig Lee Slingluff
-
依托单位:
CLINICAL TRIAL: A PHASE II TRIAL OF VACCINATION WITH PEPTIDES FOR PATIENTS WITH
-
批准号:8167154
-
项目类别:
-
资助金额:$0.8万
-
财政年份:2010
-
负责人:Craig Lee Slingluff
-
依托单位:
A MULTIPEPTIDE VACCINE IN MELANOMA PATIENTS WITH EVALUATION OF INJECTION SITE
-
批准号:8167189
-
项目类别:
-
资助金额:$16.44万
-
财政年份:2010
-
负责人:Craig Lee Slingluff
-
依托单位:
INTRATUMORAL INTERFERON GAMMA DURING VACCINATION IN METASTATIC MELANOMA
-
批准号:8167196
-
项目类别:
-
资助金额:$1.87万
-
财政年份:2010
-
负责人:Craig Lee Slingluff
-
依托单位:
Melanoma vaccines using MHC-associated peptides
-
批准号:7913480
-
项目类别:
-
资助金额:$7.54万
-
财政年份:2009
-
负责人:Craig Lee Slingluff
-
依托单位:
CLINICAL TRIAL: A PHASE II TRIAL OF VACCINATION WITH PEPTIDES FOR PATIENTS WITH
-
批准号:7951467
-
项目类别:
-
资助金额:$2.34万
-
财政年份:2009
-
负责人:Craig Lee Slingluff
-
依托单位:
A MULTIPEPTIDE VACCINE IN MELANOMA PATIENTS WITH EVALUATION OF INJECTION SITE
-
批准号:7951515
-
项目类别:
-
资助金额:$22.91万
-
财政年份:2009
-
负责人:Craig Lee Slingluff
-
依托单位:
CLINICAL TRIAL: EVALUATION OF CYCLOPHOSPHAMIDE WITH PEPTIDE VACCINES IN PARTICIP
-
批准号:7951465
-
项目类别:
-
资助金额:$4.09万
-
财政年份:2009
-
负责人:Craig Lee Slingluff
-
依托单位:
CLINICAL TRIAL: A PHASE II TRIAL OF VACCINATION WITH PEPTIDES FOR PATIENTS WITH
-
批准号:7718549
-
项目类别:
-
资助金额:$2.59万
-
财政年份:2008
-
负责人:Craig Lee Slingluff
-
依托单位:
EVALUATION OF CYCLOPHOSPHAMIDE WITH PEPTIDE VACCINES IN PARTICIPANTS W/MELANOMA
-
批准号:7718546
-
项目类别:
-
资助金额:$24.04万
-
财政年份:2008
-
负责人:Craig Lee Slingluff
-
依托单位:
CLINICAL TRIAL: EFFECTS OF LOCAL GM-CSF IN-ADJUVANT ON DENDRITIC CELLS IN MELANO
-
批准号:7718603
-
项目类别:
-
资助金额:$0.09万
-
财政年份:2008
-
负责人:Craig Lee Slingluff
-
依托单位:
CLINICAL TRIAL: PHASE 2: CCI-779 IN COMBINATION WITH BEVACIZUMAB IN STAGE III OR
-
批准号:7718577
-
项目类别:
-
资助金额:$0.52万
-
财政年份:2008
-
负责人:Craig Lee Slingluff
-
依托单位:
Targeted Molecular Therapeutics for Melanoma: CCI-779 and Bevacizumab
-
批准号:7275879
-
项目类别:
-
资助金额:$30.38万
-
财政年份:2007
-
负责人:Craig Lee Slingluff
-
依托单位:
SYNTHETIC HELPER PEPTIDE VACCINES FOR PATIENTS WITH STAGE IV MELANOMA
-
批准号:7606671
-
项目类别:
-
资助金额:$3.21万
-
财政年份:2007
-
负责人:Craig Lee Slingluff
-
依托单位:
TRANSDERMAL ADJUVANT ADMINISTRATION OF PEPTIDE-BASED VACCINE, HIGH-RISK MELANOMA
-
批准号:7606692
-
项目类别:
-
资助金额:$2.67万
-
财政年份:2007
-
负责人:Craig Lee Slingluff
-
依托单位:
海外基金